secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001731122-25-000067
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh
------------------------------------------------------------------------

- Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).
- Base salary of $280,000 per year; performance bonus up to $40,000 annually, pro-rated for 2025.
- Equity incentive grant of 250,000 stock options vesting quarterly over eight quarters; discretionary equity grant on first anniversary.
- If terminated without cause or for good reason: six months base salary, COBRA reimbursement for 6 months, accelerated vesting of time-based awards.
- Simon Tarsh removed as Interim CFO in connection with Fuentes' appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/e6282_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer